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Abstract
Background: Osteosarcoma is the most common malignant primary bone tumour in young adult treated by neo adjuvant
chemotherapy, surgical tumor removal and adjuvant multidrug chemotherapy. For correction of soft tissue defect
consecutive to surgery and/or tumor treatment, autologous fat graft has been proposed in plastic and reconstructive
surgery.
Principal Findings: We report here a case of a late local recurrence of osteosarcoma which occurred 13 years after the initial
pathology and 18 months after a lipofilling procedure. Because such recurrence was highly unexpected, we investigated the
possible relationship of tumor growth with fat injections and with mesenchymal stem/stromal cell like cells which are
largely found in fatty tissue. Results obtained in osteosarcoma pre-clinical models show that fat grafts or progenitor cells
promoted tumor growth.
Significance: These observations and results raise the question of whether autologous fat grafting is a safe reconstructive
procedure in a known post neoplasic context.
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Introduction
In plastic and reconstructive surgery, autologous fat grafting
enables soft tissue augmentation and is increasingly used for
cosmetic indications but also for correction of defect following
tumor treatment. This procedure proposed by Coleman was
applied first for facial remodelling and more recently for breast
augmentation [1,2]. This lipofilling procedure is usually consid-
ered as a safe procedure and does not require a permit application.
Indeed it consists of autologous tissue injection in a site of defect,
directly after harvesting without ex vivo expansion.
The only safety concern which was predicted in 1987 by the
American Society of Plastic and Reconstructive Surgeons was
that fat grafting may compromise breast cancer detection by
inducing microcalcifications. In fact a recent clinical study has
demonstrated that previous breast augmentation leads to
difficulties for breast cancer detection and for tumor management
and reconstruction procedure [3]. Concerning breast reconstruc-
tion after mastectomy, fat injection seems to be accepted, but it
remains controversial to treat cosmetic sequelae after conserva-
tive breast surgical treatment [4,5]. Indeed one safety question
concerns the potential risk of recurrence caused by fat injection
side effect, but this question remains unanswered for breast
cancer as relapse incidence is already high for certain groups of
patients.
In contrast, late local recurrence is an unexpected event after
complete remission of an osteosarcoma. Only 5% of patients with
recurrent disease have local recurrence and such event occurs at a
median time ranging from 6 to 28 months as reported by Ferrari
et al. [6]. Additionally these authors have observed a disease free
survival of 46% stable from the 8th to 12th year. In another study,
Meyers et al. have found the latest recurrence at the 9th year [7].
Bielack et al. have only reported 2 cases of late relapse over the 204
patients followed during 10 years; both were distant relapses with
no local recurrence [8]. In fact, late local recurrence (after 15 to 20
years) has only been reported for low grade parosteal osteosarco-
ma subtype [9].
Here we report an unexpected local osteosarcoma relapse
which occurred at the exact site of autologous fat grafts in a
female patient who did not present any predictive factor of local
recurrence. Previous experimental osteosarcoma models have
been widely used to set up new therapeutic protocols and to
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understand the interactions between osteosarcomas and their
environment [10,11,12]. In this study, pre-clinical experiments
were set up using a human osteosarcoma model induced in
athymic nude mice to determine whether tumor growth may be
modified by fat grafts. Because we observed that tumor growth
was promoted by fat injection, we investigated the role of
mesenchymal stem/stromal cells (MSCs), as fat tissue is a well-
known source of MSC-like cells whose implication in cancer is
controversial.
Materials and Methods
Ethics statement
- A surplus of human adipose tissue was used to isolate human
mesenchymal stem cells and for injection in mice. This fat surplus
was obtained from a female patient in the course of an aesthetic
abdominal liposuction. The oral consent of the patient was
obtained for the use of fat sample for research. A written consent
was not necessary because it was anonymized unlinked research in
accordance with French law (Art. L. 1245-2 du code de la sante´
publique, Loi nu 2004-800 du 6 aouˆt 2004 Journal Officiel du 7
aouˆt 2004).
- All research involving animals were conducted following the
guidelines (named ‘‘Charte nationale portant sur l’e´thique de
l’expe´rimentation animale’’) of the French ethical committee
(named ‘‘Comite´ national de re´flexion e´thique sur l’expe´rimenta-
tion animale’’) and have been approved by the committee named
CEEA.PdL.06.
Coleman’s procedure
Coleman’s procedure was performed over one female patient
under general anesthesia [1]. The fat donor site was the abdominal
subcutaneous tissues. The fat was taken using a cannula connected
to a 10 ml Luer-Lock syringe. A steel stopper device helped to
maintain the vacuum in the syringe during the aspiration phase.
The sampling syringes were sealed and centrifuged at 3000 rpm
for 3 min. After centrifugation the sample was separated into 3
layers: the upper yellow layer composed of oil from destruction of
fat fragment, the middle layer composed of the adipose tissue graft
and the bottom one composed of blood. The top and bottom
layers were discarded and fatty tissue is injected through 1-mm
incisions in subcutaneous and muscle tissue to obtain a filling
effect.
Cell culture
SaOS2 cell line. The human osteosarcoma cell line SaOS2
was initially derived from an 11-year old Caucasian girl [13]. The
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Biowhittaker, Verviers, Belgium) with 1% antibiotic
mixture (Penicillin 100 U/ml and Streptomycin 100 mg/l;
Invitrogen, Cergy-Pontoise, France) supplemented with 10%
fetal bovine serum (FBS, Dominique Dutscher, Brumath,
France), at 37uC in a humidified atmosphere (5% CO2/95%
air). The cells were harvested at confluence with trypsin (0.5 g/l)/
EDTA (0.2 g/l) (Cambrex Bio Sciences, Verviers, Belgium).
POS-1 cells. The murine osteosarcoma cell line POS-1,
derived from osteosarcoma which spontaneously developed in
C3H/HeN mice was kindly provided from Kanagawa Cancer
Center (Kanagawa, Japan [14]). The cells were cultured in RPMI
1640 medium (Biowhittaker, Verviers, Belgium) supplemented
with 10% FBS, at 37uC in a humidified atmosphere (5% CO2/
95% air). The cells were harvested at confluence with trypsin
(0.5 g/l)/EDTA (0.2 g/l).
C3H10T1/2 MSCs. These cells were originally derived from
C3H/HeN mouse embryos and were purchased from the
American Type Culture Collection (CCL-226, Manassas, VA,
USA). They represent a model of murine MSCs, able to
differentiate into adipocytes, chondrocytes and osteoblasts [15].
They were cultured in alpha-MEM (Invitrogen, Cergy-Pontoise,
France) with 10% FBS.
Co-culture. Thirty thousands osteosarcoma POS-1 cells were
seeded in 24 well-plates with RPMI 1640 medium supplemented
with 10% FBS. Murine C3H10T1/2 MSCs (15 000) were seeded
in BD Falcon Cell Culture Insert (pore size 3 microns, BD
Biosciences, Erembodegem, Belgium) with alpha-MEM
supplemented with 10% FBS. One day after cell seeding, the
murine MSCs were incubated with POS-1 cells with RPMI 1640
medium supplemented with 5% FBS. A trypan blue cell counting
was then performed on POS-1 cells 24 and 72 hours later.
Isolation and characterization of human MSCs from
adipose tissue
Human fat sample was obtained from one female patient in the
course of an aesthetic abdominal liposuction with her informed
consent for the use for anonymized unlinked research. The donor
had no significant medical history. Fat was removed using the
Coleman’s procedure and 200 ml of centrifuged fat were plated in
25 cm2 flask in 5 ml of alpha-MEM supplemented with 0.5 ml of
FBS and 0.05 ml of antibiotics (Penicillin 100 U/ml and
Streptomycin 100 mg/l; Invitrogen, Cergy-Pontoise, France). To
remove non adherent cells, the cells were washed after 24 hours
three times and then supplemented with fresh medium. For
phenotypic characterization, surface antigen markers were ana-
lyzed by flow cytometry on MSCs. Cells were washed twice with
phosphate-buffered solution (PBS) containing 0.4% bovine serum
albumin (BSA) before staining with the following antibodies:
FITC-conjugated anti-CD90 (Biosciences, Erembodegem, Bel-
gium), PE-conjugated anti-CD105, FITC-conjugated anti-CD34
and PE-conjugated anti-CD45 (Biolegend, San Diego, CA, USA).
Differentiation potential assessment. After expansion, the
cells were seeded into chamber slides (LabTek, Nunc) and
stimulated by osteogenic, adipogenic and vascular smooth
muscle inducing media. Osteogenic medium consisted of alpha-
MEM medium complemented by 10% FBS, 50 mg/ml freshly
prepared ascorbic acid (Sigma, Saint-Quentin, Fallavier, France),
10 mM sodium-beta-glycerophosphate (Sigma) and 300 ng/ml
recombinant human BMP4 (RnD systems, Lille, France). The cells
were cultured three weeks and then mineralization was assessed by
using alizarin red and von Kossa staining [16]. After extensive
washing, cells were observed under light microscopy. Adipogenic
medium consisted of 1610-6 M dexamethasone and 0.5 mM
isobutylmethylxanthin (IBMX, Sigma). The vascular smooth
muscle fate was obtained by adding 20 ng/ml TGFb1. Nile
Red-Oil (Sigma) was used to stained lipid droplets. Monoclonal
antibodies recognizing SM-a actin (clone 1A4, Sigma), SM-a
actinin (clone 1E12, Developmental Studies Hybridoma Bank,
university of Iowa), SM22a (clone 10H12, Novocastra) and SM
myosin heavy chain (clone hsmv, Sigma) were used.
Histological analyses
Surgical specimens were fixed in 10% buffered formaldehyde
and after embedding in paraffin, 5 mm-thick sections were stained
with haematoxylin–eosin–safran solution. For presence of neutral
lipids, osteosarcoma specimens were frozen and sliced into 5 mm-
thick sections. Sections were fixed with 10% paraformaldehyde,
then rinsed in distilled water, washed in 60% isopropanol and
finally stained with Oil Red O solution (3 g/l).
Fat Graft and Osteosarcoma
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In vivo experiments
Human osteosarcoma model in nude mice. Four-week-
old female athymic mice (NMRI nu/nu; Elevages Janvier, Le
Genest St Isle, France) were housed under pathogen-free
conditions at the Experimental Therapy Unit (Faculty of
Medicine, Nantes, France) following the guidelines of the French
ethical committee (CEEA.PdL.06). The mice were anesthetized by
inhalation of an isoflurane-air mix (2%, 1 l/min) before any
surgical manipulation. Human osteosarcoma SaOS2 cells were
injected in the tibial anterior muscle (86106 cells in 50 mL PBS) of
athymic mice to induce a primary tumor. Then fragments (0.02 g)
of this primary tumor were transplanted next to the tibia of mice of
the same athymic strain to induce osteosarcoma development [11].
Eight days after fragment transplantation, tumors were detected.
Then they were either injected with 100 ml of fat harvested from
one female patient following the Coleman’s procedure or injured
with empty cannula. The tumor volume was calculated by the
measure of 2 perpendicular diameters with a vernier caliper and
calculated with the formula (l26L)/2 where l and L represent
respectively the smallest and the largest diameter.
Mouse osteosarcoma model in C3H/HeN mice. Four-
week-old male C3H/HeN mice (Elevages Janvier) were housed
under pathogen-free conditions at the Experimental Therapy Unit
as described above. Subcutaneous injections of POS-1 cells
(26106) were performed in the hind footpad of the mice. In
some experiments, POS-1 cells were co-injected with C3H10T1/2
MSCs at the ratio 2/1. The tumor volume was calculated as
described above.
Results
Case report
A 17 year-old girl was admitted in our institution in August
1994 with a metaphyso-epiphyseal bone tumor of the proximal
humerus. An incisional biopsy made the diagnosis of telangiectasic
osteosarcoma (Fig. 1A), in conformity with clinical and radiolog-
ical features. The patient received pre operative chemotherapy in
respect to french protocol at this time (4 cures of Holoxan/cis
platinium). Then a limb-salvage procedure consisting of an extra
articular resection of proximal humerus with gleno-humeral
articulation was performed. The reconstruction consisted of an
arthrodesis with a vascularised scapular crest bone graft. The
histopathologic examination of the specimen concluded of clear
wide margins and no viable cells have been found out (good
response, Huvos grade 4). The patient received two more cures of
the same chemotherapeutic protocol. She has been continuously
follow-up every 6 months for 5 years then every year [Magnetic
Resonance Imaging (MRI) and chest X ray] until now.
In 2005, because of the unsightly appearance of her left arm
due to resection of soft tissue and mainly deltoid muscle (Fig. 1B),
she was referred to a reconstructive surgeon of our institution
and received three autologous fat grafts harvested from her
abdominal wall and injected circularly around the bone graft in
soft tissues (March 2005, June 2005 and January 2006). The
patient reported a good cosmetic result with a lasting increased
volume of the arm.
In August 2007, she consulted her oncologist because of pain,
inflammation and swelling at the lipofilling site (Fig. 2A). The
Magnetic Resonance Imaging (MRI) showed an extensive soft
tissue tumor (Fig. 2B). Histological analysis of the biopsy revealed
an osteosarcoma with neoplastic cells and thin osteoı¨d formation
(Fig. 2C). No lipid droplets have been observed after Oil Red O
staining of the biopsy. No distant relapses have been found out.
The patient received again 4 cures of chemotherapy (API-AI
French protocol) and a trans scapula amputation was performed
(Fig. 2D). Tumor cells still responded well to chemotherapy
(Huvos grade 3) and no post operative chemotherapy was
proposed because of severe renal deficiency after pre operative
chemotherapy. Despite the high rate of necrosis, the pathologist
was able to see wide area of haemorrhage compatible with
telangiectasic subtype (Fig. 2E). One year after the surgery the
patient does not present any sign of local or distant relapse.
Figure 1. Telangiectasic osteosarcoma and post surgical defect. (A) Photomicrograph of the initial telangiectasic osteosarcoma showing
proliferation of neoplastic cells, focal osteoı¨d formation (*) and telangiectasic space containing blood (X) (optical microscopy, HES staining,6100). (B)
Post-surgical defect of the left arm in January 2005, 2 months before the first lipofilling procedure.
doi:10.1371/journal.pone.0010999.g001
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Osteosarcoma growth is increased by fat injection
As a result of this surprising clinical case, we wondered whether
fat graft was the cause of the local late osteosarcoma recurrence. In
a first attempt to test this hypothesis, we tested whether a fat
sample which is used for an autologous fat graft can modify the
growth of human osteosarcoma induced in immunodeficient mice.
First, athymic nude mice were injected with human SaOS2
osteosarcoma cells in muscle leading to tumor development in less
than 50% of mice. To obtain a greater bone tumor incidence,
fragments of a primary tumor induced by SaOS2 cell injection
were transplanted next to the tibia of recipient mice of the same
strain. Twenty one mice were transplanted with human osteosar-
coma fragments of the same weight, then were divided into 3
groups: the control SaOS2 group just received tumor fragment at
day 0; the SaOS2 + fat group was injected with human fat into the
tumor site at day 8 after transplantation when a progressive tumor
was detected (size .100 mm3); the SaOS2 + cannula group was
transplanted with tumor fragment at day 0, then at day 8 the
tumors were injured with an empty cannula to reproduce potential
inflammatory process; and a group of three mice was injected only
with human fat in the tibial muscle. Results of tumor progression
are shown in figure 3. In the control SaOS2 group, osteosarcoma
developed rapidly reaching a mean volume of 1393 mm3 23 days
after tumor implantation (Fig. 3A). Tumor growth was greatly and
significantly increased at day 21 after tumor induction in the group
that received fat injections (Fig. 3B). As the fat injection was
realized with a cannula which may have induced inflammation, a
group of injured osteosarcoma was studied in the same conditions.
In this case, the inflammation caused by cannula injury did not
change osteosarcoma growth as compared to the control SaOS2
group with uninjured osteosarcoma (Fig. 3C). The tumor size
increase observed in the SaOS2 + fat group was not due to the fat
mass itself as only reduced and stable volumes (less than 200 mm3)
were observed with fat injections alone into naive control mice
Figure 2. Osteosarcoma recurrence at the lipofilling site. (A) Inflammatory and swelling of the lipofilling site at the left arm after 4 cures of
chemotherapy. (B) T2 weighted MRI shows extensive circular soft tissue tumor of the left arm, measuring 12 cm by 10 cm. (C) Photomicrograph of
the biopsy specimen at the recurrent tumor site showing high grade malignant cell proliferation and thin osteoı¨d formation (optical microscopy, HES
staining,6100). (D) Photograph of the open resected tumor with tumor mass (*) around the left humerus diaphisis and peripheral fat engraftment (X)
(E) Histology of resected tumor specimen (optical microscopy, HES staining,6100).
doi:10.1371/journal.pone.0010999.g002
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(Fig. 3D). Moreover, we could observe that animals which received
fat grafts in osteosarcoma tumors were more homogeneous in their
tumor progression as compared with control groups (SaOS2 and
SaOS2 + cannula).
Histological analyses revealed few but large adipocytes between
the neoplastic cells for tumor specimens of the SaOS2 + fat group
(Fig. 4A), whereas only small adipocytes were identified within
fibrotic areas and not between neoplastic cells within tumor
specimens of the SaOS2 + cannula group (Fig. 4B) or control
SaOS2 group (data not shown). The proportion of these large
adipocytes seems too small to explain the tumor size increase
which was observed in the SaOS2 + fat group. Then we may
hypothesize that fat injections have stimulated osteosarcoma cell
proliferation.
MSC-like cells are present in the injected fatty tissue
One hypothesis for the stimulation of osteosarcoma growth by fat
injection may lie to the presence of MCSs in the injected fatty tissue.
An aliquot of the fat tissue which was injected into SaOS2-bearing
mice was tested in culture for the presence of adherent cells. Such
cells were obtained and analyzed by flow cytometry. At passage 3,
these cells were positive for the MSC markers CD105 and CD90
(Fig. 5A) and simultaneously negative for the hematopoietic markers
CD45 and CD34 (data not shown). Moreover, these cells
differentiated into the osteoblastic and adipocytic cells as well as
muscle cells from vascular smooth muscle lineage as shown in
figure 5. Indeed, according to the type of induction the presence of
mineralized nodules was identified by either von Kossa or alizarin
red staining and adipocytes by their content in lipid droplets
positives labelled by Nil Red-Oil. In addition, MSC-like cells were
able to give rise vascular smooth muscle (VSM) cells since
expression of cytoskeletal molecules specific of VSM lineage such
as SM22a, SM myosin heavy chain, SM-a actin and SM-a actinin
increased dramatically after VSM induction. Therefore, adherent
cells-derived from fat had characteristics similar to what it is largely
described for bone marrow MSC [17].
After passage 8, these MSC-like cells were injected in three mice
and the three intramuscular injections of two million cells per
mouse did not induce tumor development after 60 days. These fat-
derived cells maintained long-term self-renewal (.20 passages),
but they have lost the CD105 expression as early as passage 6
showing rapid phenotypic change in culture.
Figure 3. Fat injections into osteosarcoma induced in nude mice. (A) Six mice were considered as control tumors (SaOS2). (B) A group of 6
mice was injected at the tumor site with human fat harvested by the Coleman’s technique (SaOS2 + fat). (C) A control group of 6 mice was injured
with empty cannula at the tumor site. (D) Another group of 3 mice received the fat alone. Arrows indicate day 8 after transplantation when fat
injections or cannula injuries were performed. Statistical analyses were calculated with the Kruskal-Wallis test (nonparametric ANOVA) using
GraphPad InStat v3.02 software. The p value was less than 0.05 for SaOS2 + fat versus SaOS2 alone or versus SaOS2 + cannula at day 21, but was not
significant for SaOS2 alone versus SaOS2 + cannula.
doi:10.1371/journal.pone.0010999.g003
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Injections of MSCs with osteosarcoma cells increase
tumor progression
To determine whether MSCs can interact with osteosarcoma
cells and may modulate the early tumor development, we
compared the tumor progression induced in mice by injection of
osteosarcoma cells alone or with MSCs. For this experiment, we
tested mouse osteosarcoma POS-1 cells rather than human SaOS2
cells because their injection in mouse footpad led to a greater
tumor indidence (80% versus 50%). The POS-1 cells and
C3H10T1/2 MSCs have been derived from the C3H/HeN
mouse strain, allowing us to perform this experiment in a syngenic
immunocompetent model. Eighteen C3H/HeN mice were
divided into 3 groups: one control group was injected with
26106 osteosarcoma POS-1 cells (POS-1 group); a second control
group received 106 C3H10T1/2 cells (C3H10T1/2 MSC group);
and mice in the test group were co-injected with POS-1 and
C3H10T1/2 cells at the above mentioned concentrations
(POS-1 + C3H10T1/2 MSC). Results of individual tumor
progression showed a disparity in the time course of tumor onset
in the POS-1 group (Fig. 6A): 5 animals out of 6 developing a
tumor at different time (from day 15 to 32). On the contrary, all
the animals in the POS-1 + C3H10T1/2 MSC group developed a
tumor early after cell injection (around day 10) with the same time
of onset (Fig. 6A); while MSCs alone did not induce any tumor
development (data not shown). The tumor development appeared
earlier and more homogenously in the POS-1 + C3H10T1/2
MSC group than in the POS-1 group. The median tumor volume
was three times higher in the POS-1 + C3H10T1/2 MSC group
than the one in the POS-1 group at day 19 (775 versus
218.5 mm3) and the difference was very significant (p = 0.0076
with Mann-Whitney test using GraphPad InStat v3.02 software).
Similar results were obtained using a co-injection of rat MSC-like
cells and rat osteosarcoma cells in the footpad of nude mice: earlier
onset and faster growth of tumors as compared to osteosarcoma
cells injected alone (Figure S1A).
We wondered whether MSCs may change the proliferation rate
of osteosarcoma cells. Then C3H10T1/2 MSCs and POS-1 cells
were co-cultured in vitro at a 1:2 ratio without cell contact. The
number of blue stained POS-1 cells did not change when
comparing co-cultured and cultured alone POS-1 cells; whereas
the number of POS-1 live cells was significantly increased when
co-cultured with C3H10T1/2 MSCs as compared to POS-1
cultured alone (Fig. 6B). Similarly the proliferation of rat
osteosarcoma cells (OSRGA) was increased when co-cultured
with rat MSC-like cells under same experimental conditions as
described above (Figure S1B). Therefore MSC-like cells secreted
Figure 4. Identification of lipid droplets in osteosarma specimens. (A) Photomicrograph of a tumor specimen from the SaOS2 + fat group
showing large red lipid droplets. (B) Photomicrograph of a tumor specimen from the SaOS2 + cannula group showing small red lipid droplets (optical
microscopy, Oil Red O staining).
doi:10.1371/journal.pone.0010999.g004
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one or several soluble factors which have promoted osteosarcoma
cell proliferation in vitro.
Discussion
A patient in complete remission of an humerus telangiectasic
osteosarcoma since ten years consulted for a cosmetic correction
by lipofilling. Three injections of autologous fat grafts harvested by
the Coleman’s technique were realized and few months after the
last one, a local recurrence of osteosarcoma occurred 13 years
after the initial treatment. Late local recurrence of an osteosar-
coma is a very unexpected event after complete remission and 10
years of follow-up. To our knowledge this is one of the longest
delay reported between remission and local recurrence, another
case being reported by Bacci et al. [18]. The patient reported here
did not present any predictive factor of local recurrence. It was a
telangiectasic osteosarcoma subtype and wide margins were
obtained after extra articular monobloc resection, both considered
as good predictive factors of disease free survival [8,18]. Even a
bad response to chemotherapy is not considered as a bad
prognostic factor for late relapse (after 4 years) instead of earlier
relapse [19,20]. Thus, this local recurrence of telangiectasic
osteosarcoma at the exact area of autologous fat grafts performed
18 months before raised the question of their possible relationship.
Despite the widespread clinical use of Coleman’s lipofilling
technique, very little is known about its consequence on tissue
environment after tumor resection. The only published data
concerned conservative treatments in breast cancer patients in
which this technique represents an advance, but in these cases the
correlation between fat transfer and recurrent breast cancer is
difficult to analyze [2,21,22,23,24]. Motrescu and Rio have
described a vicious cycle between adipocytes and cancer cells:
the last ones induce secretion by adipose tissue of Matrix
Metalloproteinase 11 which in turn favors cancer cell survival
and tumor progression by changing the tumor surrounding
environment [25]. To investigate the possible relationship between
fat graft and osteosarcoma growth, an experimental model
reproducing the clinical case of human fat injection in osteosar-
coma was set up using human SaOS2 osteosarcoma cells in
athymic mice. The human fat tissue was harvested from a patient
and injected following the Coleman’s procedure. Results showed
that osteosarcoma growth was significantly increased by fat
injection whereas fat alone produced only small and stable
volumes at injection sites in naive mice. Several hypotheses could
explain these observations. On one hand, fat may promote
angiogenesis thereby interfering with tumor growth. Indeed,
Vascular Endothelial Growth Factor (VEGF) which is expressed
in the interstitial connective tissue of fat grafts favours graft
Figure 5. Characterisation of human fat derived MSC-like cells. (A) Flow cytometry analysis showed CD105 and CD90 positive cells after the
third passage in culture. In addition, multipotential capacities of MSC-like cells were tested by inducing cells to differentiate into osteoblastic cells
capable to mineralize, adipocytes and vascular smooth muscle (VSM) cells. (B) Mineralized nodules were identified as black spots using von Kossa
silver staining or (C) as red spots using alizarin red staining after incubation of fat derived MSC-like cells in osteogenic differentiation medium.
Adipocytes containing small Nil Red-positive lipid droplets were easily observed upon adipogenic conditions (D) whereas non induced cells were not
labeled (E). In contrast to non induced cells (F), those cultured upon VSM conditions (G) generated elongated cells positive for several VSM markers
such as SM-a actin, SM22a, SM-a actinin and SM myosin heavy chain.
doi:10.1371/journal.pone.0010999.g005
Fat Graft and Osteosarcoma
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e10999
survival [26], but can stimulate growth, invasion and metastasis of
solid tumors [27,28]. In another hand, adipocytes highly express
Adiponectin (also designed as adipose most abundant gene
transcript) which was shown to stimulate Receptor Activator of
NF-kB Ligand (RANKL or TNFSF11) and inhibit Osteoprote-
gerin expression in osteoblasts [29]. Therefore fat may regulate
two bone resorption mediators which are highly implicated in the
development of bone tumors [30]. Indeed blocking RANKL by
soluble RANK [31,32,33] or by the decoy receptor Osteoprote-
gerin [11,34,35,36,37] was proven to be effective in several in vivo
models of bone tumors and leads to the clinical development of a
fully-humanized monoclonal antibody directed against RANKL
(Denosumab) [38].
In addition, the role of MSC-like cells which are contained in
fatty tissue must be considered [39]. Our study showed that the fat
harvested following Coleman’s procedure contains progenitor cells
which share numerous characteristics with MSCs. They were
positive for the phenotypic markers CD90 and CD105 and
simultaneously negative for the hematopoietic markers CD45 and
CD34. They showed ability to survive in long term culture without
producing tumor in vivo and to differentiate in vitro into the
osteoblast lineage. Adipose-derived stem/stromal cells (designed
ADSCs or ASCs) are proposed as cellular agent to enhance
angiogenesis after ischemic injury [40,41] or to promote survival of
fat graft for breast augmentation or reconstruction [42], but
additionally they could promote migration and invasion of breast
cancer cells [43]. The effect of bone marrow-derived MSCs has
been studied on osteosarcoma development by injection in the
caudal vein of nude mice bearing SaOS2 cell-induced osteosar-
coma: the addition of MSCs has promoted tumor growth and
pulmonary metastasis in vivo [44]. In our study, we used a complete
syngeneic model with POS-1 osteosarcoma cells and C3H10T1/2
MSCs which have been derived from C3H/HeN mice and were
injected into mice of the same strain. The osteosarcoma onset and
incidence were greatly enhanced by C3H10T1/2 MSC presence.
Djouad F et al. have shown an immunosuppressive effect of
primary or C3H10T1/2 MSCs on tumor growth: B16 melanoma
cells have proliferated into allogeneic C3H/HeN mice only when
they have been co-injected with MSCs otherwise they have been
rejected [45]. Into a syngeneic tumor model, C3H10T1/2 MSCs
have induced an earlier onset of tumors but did not interfere with
the tumor growth kinetic [46]. Using a co-culture method without
cell contact, we observed that C3H10T1/2 MSCs promoted POS-
1 cell proliferation by secreting one or several soluble factors. We
noted similar observations like earlier onset of tumors in a
xenogeneic model and greater proliferation in vitro when rat
osteosarcoma cells were combined with rat MSC-like cells.
Numerous soluble factors have to be considered as MSC
Figure 6. Mouse MSCs interact with osteosarcoma cells. (A) Evolutions of the tumor volume induced into the footpad of C3H/HeN mice. Mice
of the control group (POS-1) received osteosarcoma POS-1 cells alone, while POS-1 cells were associated with C3H10T1/2 MSCs at a ratio of 2:1 in the
POS-1 + C3H101/2 MSC group. (B) POS-1 osteosarcoma cells and C3H/10T1/2 MSCs were co-cultured without cell-cell contact. The POS-1 cell
proliferation was analyzed by trypan blue cell counting after 24 and 72 hours of co-culture. Results are presented as proliferation percentages
relatively to the total number of POS-1 cells cultured alone. Error bars represent standard deviations and asterisks indicate significant differences
between means (* for p,0.05 and ** for p,0.01).
doi:10.1371/journal.pone.0010999.g006
Fat Graft and Osteosarcoma
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e10999
mediators able to modify tumor cell proliferation or the tumor
environment. Among them, the insulin growth factor, the
fibroblast growth factor, the interleukin Il-6, the chemokine
CCL5 (RANTES) and the matrix metalloproteinases MMP-2 and
MT1-MMP are few of the mediators that could have a particular
role in bone tumor development [47,48,49]. Further studies have
to be performed to identify the MSC mediators acting on
osteosarcoma cells. To address this point, the main difficulty is
that the panel of cytokines and growth factors secreted by MSCs is
likely to be different in vitro and in vivo because their expression can
be modulated by inflammatory mediators in vivo [50].
Controversial results have been reported when MSCs have been
injected into mice with induced tumor, resulting either in
promotion or inhibition of tumor growth depending on the
studies. Antitumoral action of rat MSCs on rat gliomas has been
reported by Nakamura et al. [51]. In that report, MSCs have been
responsible for prolonged survival of glioma-bearing rats. Similarly
and somewhat to their own surprise, Khakoo AY et al. [52] have
obtained also an antitumorigenic effect of human MSCs on
Kaposi’s sarcomas which have been induced on nude mice. Since
their first warning, Djouad F et al. have also reported that the
immunosuppressive effect of mouse MSCs in vivo depends on
environmental parameters and that even ‘‘a low but relevant
amount of MSCs may induce tumor rejection’’ [46]. Therefore the
effect of MSCs within tumors seems unpredictable and dependant
of microenvironment signals. By exploring the interaction of
MSCs with the tumor environment, new therapeutic options could
be provided [53].
In an osteosarcoma experimental model, Naumov et al. have
shown that switch from non angiogenic to angiogenic phenotype
could be a biologic behavior associated to the clinical expression of
a quiescent tumor [54]. Assuming that cancer stem cell-like theory
in bone sarcoma is correct [55,56], their presence at the site of the
primary tumor after treatment is in agreement with a ‘‘supposed’’
good response chemotherapy and wide monobloc surgery as in our
patient. Despite the lack of biological data on the mechanism by
which cancer stem cells drive the tumor growth, the modulation of
microenvironment induced by the fat graft could interfere with the
biological behaviour of this sub-population. The preclinical
experimental designs used in the present study mimic surgical
procedure for lipofilling enabling to study in vivo interaction
between fat and osteosarcoma cells, but do not mimic the late and
local recurrence of osteosarcoma after a long lasting remission as
observed in the clinical case reported here. Further experimental
investigations are necessary to understand the mechanism
regulating the interactions between the graft, the tissue recipient
and quiescent tumor cells. However surgery associating inflam-
matory process could be directly responsible for the reactivation of
dormant tumor cells [57,58]. This last assumption attributes a
minor or non role to adipose tissue but constitutes anyway a
warning concerning the fat grafting or any other surgical
procedure in a post-neoplastic environment.
In conclusion, because of the unexpected late local recurrence
of an osteosarcoma at the exact area of autologous fat grafts and
the stimulation of osteosarcoma tumor growth by fat or MSC-like
cells in experimental models, clinician must be aware of the
possible long term local relapse of tumor after an autologous fat
graft which is usually considered as a safe procedure.
Supporting Information
Figure S1 Rat MSCs interact with osteosarcoma cells. (A)
Evolutions of the tumor volume induced into the footpad of nude
mice (NMRI nu/nu; Elevages Janvier, Le Genest St Isle, France).
The OSRGA cells were derived from a transplantable rat
osteosarcoma model originally induced by radiation [11].
Relatively undifferentiated mesenchymal cells (MSC-like cells)
were obtained from calvaria of newborn rat (2 days old Sprague-
Dawley rat, Charles River, L’Arbresle, France) as previously
described. Mice of the control group (OSRGA) received 106
OSRGA cells alone, while OSRGA cells were associated with
calvaria-derived MSC-like cells at ratio 2:1 in the OSRGA + MSC
group. A third group received 0.56106 MSC-like cells alone and
have not developed any tumor after 85 days (data not shown). The
significance test is not performed as only three mice per group
were included in this preliminary experiment. (B) OSRGA cells
and calvaria-derived MSC-like cells were co-cultured without cell-
cell contact. The OSRGA cell proliferation was analyzed by
trypan blue cell counting after 24 and 72 hours. Results are
presented as proliferation percentages relatively to the total
number of OSRGA cells cultured alone. Error bars represent
standard deviations and asterisks indicate significant differences
between means (p,0.01).
Found at: doi:10.1371/journal.pone.0010999.s001 (0.50 MB
TIF)
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